Clinical trials: ifosfamide
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Trial name
- NCT00720109
- Testing
- Asparaginase, Cyclophosphamide, Cytarabine
- Where
- 134 sites in United States, Australia and 3 more
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer, Kidney Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Kidney Cancer, Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00002764
- Testing
- filgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- Sweden
- Volunteers
- 340 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Newly Diagnosed High Risk Neuroblastoma
Response-based Treatment of High-risk Neuroblastoma
The purpose of this study is to improve outcome of high risk neuroblastoma by tailoring the treatment intensity of tandem high dose chemotherapy according to the treatment response to induction chemotherapy.
- Trial name
- NCT02771743
- Testing
- Cisplatin, Doxorubicin, Etoposide
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Samsung Medical Center
Metastatic Sarcoma, Recurrent Sarcoma
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent).
- Conditions
- Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
- Trial name
- NCT04199026
- Testing
- Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Pediatric
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has largely changed due to extensive genetic research in recent years: ALL is now considered to be a very heterogeneous disease group.
- Trial name
- NCT03643276
- Testing
- Blinatumomab, Bortezomib, Cyclophosphamide
- Where
- 115 sites in Australia, Austria and 6 more
- Volunteers
- 5,000 people
- Sponsor
- Martin Schrappe
Pediatric Anaplastic Large Cell Lymphoma
CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL
A prospective study on the efficacy of modified ALCL99 regimens in the treatment of the current Chinese pediatric and adolescent high-risk ALCL and compared with our historical data.
- Trial name
- NCT04881838
- Testing
- P regimen, Course A1 + Vin, Course B1 +Vin
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Children's Cancer Group, China
Progression-free Survival, Overall Survival
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
Advanced soft tissue sarcoma patients who have previously recieved anthracyclines might still benefit from doxorubicin, ifosfamide and dacarbazine.
- Conditions
- Progression-free Survival, Overall Survival, Toxicity
- Trial name
- PDVPSTS (NCT03342300)
- Testing
- pegylated liposomal doxorubicin, pirarubicin
- Where
- China
- Sponsor
- Peking University People's Hospital
Germ Cell Tumor, Teratoma
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned…
- Conditions
- Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma
- Trial name
- NCT02375204
- Testing
- paclitaxel, ifosfamide, cisplatin
- Where
- 125 sites in United States, Australia and 10 more
- Volunteers
- 420 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
Large Cell Lymphoma Pilot Study III
The main purpose of this study is to find out if it is feasible to deliver a multi-agent chemotherapy regimen which features a shorter, more intensive, immunophenotype-directed approach, and includes an intensification phase with…
- Trial name
- NCT00187070
- Testing
- Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine, Stem cell transplant,, Radiation Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- St. Jude Children's Research Hospital
Rhabdomyosarcoma
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
This study will treat participants with newly diagnosed, low, intermediate and high risk rhabdomyosarcoma (RMS) using multi-modality risk-adapted therapy with standard or intensified dose chemotherapy, radiation and surgical…
- Trial name
- NCT01871766
- Testing
- Vincristine, Dactinomycin, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 115 people
- Sponsor
- St. Jude Children's Research Hospital
Sarcoma
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide or doxorubicin is more effective for advanced or metastatic soft…
- Trial name
- NCT00003212
- Testing
- doxorubicin hydrochloride, ifosfamide
- Where
- 23 sites in Belgium, Denmark and 8 more
- Volunteers
- 780 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leukemia, Lymphoma
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00039130
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 31 sites in United States
- Volunteers
- 105 people
- Sponsor
- Alliance for Clinical Trials in Oncology
T-lymphoblastic Lymphoma, Relapsed Disease
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
To evaluate the safety and efficacy of Venetoclax plus IM2 regimen for relapsed and refractory T lymphoblastic lymphoma/leukemia.
- Conditions
- T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma, Refractory Leukemia
- Trial name
- NCT05576532
- Testing
- BCL2 Inhibitor plus IM2 regimen
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk…
- Trial name
- HR-NBL2 (NCT04221035)
- Testing
- Vincristine, Carboplatin, Etoposide
- Where
- 142 sites in Australia, Austria and 18 more
- Volunteers
- 800 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Tumors, Solid Malignant Tumors
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid…
- Conditions
- Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
- Trial name
- NCT02432274
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Limited
Extragonadal Germ Cell Tumor, Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, carboplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing them or by stopping them from dividing.
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00002558
- Testing
- filgrastim, carboplatin, etoposide
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bone Sarcoma, Embryonal Rhabdomyosarcoma
Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas
Data from 40 patients are planned to be included in the study to randomize approximately 10 patients. This study involves patients with advanced/metastatic GD2-positive rhabdomyosarcoma after progression on 1st line of…
- Conditions
- Bone Sarcoma, Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma
- Trial name
- FollowTheDIN (NCT06669013)
- Testing
- dinutuximab beta
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology